Physician profile
Daniel Dress
NPI 1699771022
$2,089.11
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2020: $577 · 2021: $699 · 2022: $231 · 2023: $428 · 2024: $17.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $351 · Education: $95.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $350.64 |
| Education | $95.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $376.66 | 2021-2023 | Vraylar |
| Pfizer INC. | $288.37 | 2020-2024 | |
| Amgen INC. | $245.28 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $203.31 | 2019-2022 | |
| Novo Nordisk INC | $200.78 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $147.32 | 2021 | |
| Lilly USA, LLC | $117.93 | 2020-2023 | Mounjaro, Trulicity |
| E.R. Squibb & Sons, L.L.C. | $77.82 | 2023 | Abilify |
| Otsuka America Pharmaceutical, INC. | $43.23 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $39.20 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $38.96 | 2022 | |
| Amarin Pharma, INC. | $34.27 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.79 | 2020-2023 | Xifaxan |
| Glaxosmithkline, LLC. | $30.68 | 2020-2023 | Arexvy |
| Eisai INC. | $30.02 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $23.06 | 2023 | Austedo |
| Abbott Laboratories | $22.90 | 2022 | |
| Horizon Therapeutics Plc | $20.85 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $19.31 | 2020 | |
| Astellas Pharma US INC | $19.17 | 2020 | |
| Biotronik INC. | $18.46 | 2023 | Rivacor 7 Dr-T, Edora 8 Dr-T, Biomonitor |
| Daiichi Sankyo INC. | $17.57 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.80 | 2019 | |
| Allergan, INC. | $14.78 | 2020 | |
| Merck Sharp & Dohme LLC | $13.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Dress listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.